Disposable device for rapid point-of-care detection and comparison of antibody responses against therapeutic proteins in rheumatoid arthritis patients
Ended Project Grant Awarded Last action
- Award ID
- R43AR081736
- Recipient
-
Conquerab Inc. UEI MCY7GFX34H75
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $517,838
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date
- Originally
- Place of performance
- Florida, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of this project is to develop a multiplexed rapid point-of-care diagnostic ("disposable device") to detect antibodies ("ABS") against therapeutic monoclonal antibodies ("mabs") approved for the treatment of rheumatoid arthritis (RA). Patients often develop anti-MAB ABS, which may abrogate the therapeutic MAB efficacy and/or cause adverse events. We have devised a unique use of chimeric proteins as capture reagents in multiplexed disposable devices, which eliminate nonspecific signal during anti-MAB AB screening, and allows direct comparison of their immunogenicity and risk assessment. The scientific approach is described in granted U.S. Patents assigned to conquerab INC. The disposable device allows AB isotype detection in less than 15 minutes from one drop of blood, and can be used before the next drug infusion (trough MAB concentration) for detection of free anti-MAB ABS, suggesting selection of dose or an alternative treatment. In addition, this disposable device will harmonize AB detection, allowing integration of patient data generated at different point-of-care facilities (big data). Existing assays for anti-MAB detection, such as enzyme-linked immunosorbent assay (elisa) require preparation of serum or plasma, sample handling, multiple steps, trained operators, may take days to provide results, and are more prone to errors. In addition, some of those assays may use an acid dissociation step, which unfortunately may denature ABS. Another problem is that the time of sample collection can vary, resulting in samples that have different concentrations of mabs in complex with anti-MAB ABS, leading to inconsistent results that cannot be validly integrated. For this phase 1 we propose development of a multiplexed diagnostic for detection of anti-MAB ABS with a proprietary technology. The test strip will also be incorporated into a patented self-contained disposable device, and tested in a clinical study with anonymized RA patients. This is an innovative strategy that can have a major impact in detecting, comparing and mitigating unwanted immunogenicity of protein-based therapies, and also in the utilization of big data for precision medicine.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$68 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $258,953 | |
| Original award | $258,953 |
Quick answers
Who received award R43AR081736?
R43AR081736 was awarded to Conquerab Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 20, 2022.
How much is award R43AR081736 worth?
$517,838 has been obligated on R43AR081736.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award